Want to see BDRX full AI Analyst Report?
Biodexa Pharmaceuticals (BDRX) Stock Statistics & Valuation Metrics
Total Valuation
Biodexa Pharmaceuticals has a market cap or net worth of $1.80M. The enterprise value is $21.72B.
- Market Cap
- $1.80M
- Enterprise Value
- $21.72B
Share Statistics
Biodexa Pharmaceuticals has 524,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 524,240
- Owned by Insiders
- ―
- Owned by Institutions
- 0.36%
Financial Efficiency
Biodexa Pharmaceuticals’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -67.29%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.34
- Return on Invested Capital (ROIC)
- -67.29%
- Return on Capital Employed (ROCE)
- -0.69
- Revenue Per Employee
- 0
- Profits Per Employee
- -567.65K
- Employee Count
- 11
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Biodexa Pharmaceuticals is -64.03. Biodexa Pharmaceuticals’s PEG ratio is -0.29.
- PE Ratio
- -64.03
- PS Ratio
- 0.00
- PB Ratio
- 5.00
- Price to FCF
- -0.03
- Price to Operating Cash Flow
- -6.89
- PEG Ratio
- -0.29
Income Statement
In the last 12 months, Biodexa Pharmaceuticals had revenue of 0 and earned -6.24M in profits. Earnings per share was -0.32.
- Revenue
- 0
- Gross Profit
- -184.86K
- Operating Income
- -8.27M
- Pretax Income
- -6.35M
- Net Income
- -6.24M
- EBITDA
- -8.08M
- Earnings Per Share (EPS)
- -0.32
Cash Flow
In the last 12 months, operating cash flow was -6.94M and capital expenditures -7,199, giving a free cash flow of -6.95M billion.
- Operating Cash Flow
- -6.94M
- Free Cash Flow
- -6.95M
- Free Cash Flow per Share
- -0.37
Dividends & Yields
Biodexa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2908.75%
- Earnings Yield
- -9.29%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- -98.60%
- 50-Day Moving Average
- 5.65
- 200-Day Moving Average
- 23.96
- Relative Strength Index (RSI)
- 39.63
- Average Volume (3m)
- 620.99K
Important Dates
Biodexa Pharmaceuticals upcoming earnings date is Apr 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 11, 2026
- Next Earnings Date
- Apr 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Biodexa Pharmaceuticals as a current ratio of 2.03, with Debt / Equity ratio of 0.53%
- Current Ratio
- 2.03
- Quick Ratio
- 2.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.05
- Interest Coverage Ratio
- -120.77
Taxes
In the past 12 months, Biodexa Pharmaceuticals has paid -102.70K in taxes.
- Income Tax
- -102.70K
- Effective Tax Rate
- 0.02
Enterprise Valuation
Biodexa Pharmaceuticals EV to EBITDA ratio is 0.32, with an EV/FCF ratio of 0.43.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.32
- EV to Free Cash Flow
- 0.43
- EV to Operating Cash Flow
- 0.43
Balance Sheet
Biodexa Pharmaceuticals has $3.21M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.21M billion.
- Cash & Marketable Securities
- $3.21M
- Total Debt
- $0.00
- Net Cash
- $3.21M
- Net Cash Per Share
- $6.12
- Tangible Book Value Per Share
- $0.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Biodexa Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 97.97%
Scores
- Smart Score
- ―
- AI Score
- 44